Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
Dr. Reddy’s Laboratories recently underwent a GMP inspection by the USFDA at its API Mirfield facility in West Yorkshire, UK, from September 1 to September 5, 2025. The inspection resulted in a Form 483 with seven observations, which the company intends to address within the stipulated timeline, potentially impacting its compliance and operational standards.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, primarily focusing on the development and manufacturing of generic medicines. The company is headquartered in Hyderabad, India, and operates globally, with a notable presence in the United States and Europe.
Average Trading Volume: 1,350,052
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.01B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.